Bristol-Myers Squibb and Samsung BioLogics announcement

[COLOR="#000000"]Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement under which Samsung BioLogics will manufacture a commercial antibody cancer drug for Bristol-Myers Squibb at its recently completed plant in Songdo Incheon, South Korea.

Financial terms were not disclosed. Technology transfer and trial production will commence soon and commercial production will immediately begin following regulatory approvals.[/color]